# NEWSLETTER (FY25 EARNINGS UPDATES)


OVERVIEW: This newsletter serves to provide review of our portfolio recommendations as Companies report FY25 earnings. Our portfolio Companies (with recommended Buy to our clients) have been able to deliver XIRR north of 53% (or c.20% returns in 5 months) despite volatility in global & domestic markets linked to Trump tariffs, war tensions, global supply chain rejigs, changing commodity prices etc.

- This newsletter is being published now as the portfolio Companies have reported their FY25 results.
- We have included our rationale / process for recommending them to our clients for the benefit of readers and only for knowledge purposes. Links to full equity research note (public version) is mentioned in the footer of respective pages.
- Please note this newsletter does not serve as current / future BUY or SELL recommendations for any of these Companies. Any BUY / SELL recommendation has been issued to our clients only as part of our paid services.

Company Name	Price at Recommendation	CMP (INR)	Upside %	
Thyrocare	683	1,050	53.7%	- 1
Standard Glass Lining	131	184	40.2%	
Danish Power	804	1,026	27.6%	
Suraksha Diagnostics	258	324	25.6%	
Thangamayil Jewellery	1,649	1,904	15.5%	
PCBL Chemical	361	398	10.2%	
Sky Gold	363	393	8.2%	
PN Gadgil	520	549	5.6%	
Dhabriya Pollywood	394	359	(8.8%)	

\*CMP, M.Cap & PE as on 30-May-2025 (source: Screener)

NIFTY 50: During Dec'24 to Mar'25, NIFTY 50 has remained flattish witnessing correction from the levels of 24,800 in Dec'24 to 21,760 in Apr'25 followed by inflows / buying which led NIFTY 50 to close at the level of 24,750 as on May'25



Volatile flows from FII's amidst global uncertainties

XIRR

the period.

of 53.3%

(Absolute return of c.20% in 5 mo.)

Note: Actual returns are higher since this does not take into effect date of investing & exits recommended at higher price during

INDEX	NIFTY 50	MIDCAP 100	SMALLCAP 100	NIFTY BANK	NIFTY AUTO	NIFTY IT	NIFTY FMCG	HEALTHCARE	OIL & GAS	REALTY
PE Ratio	22.32x	32.84x	31.65x	14.63x	24.25x	27.89x	43.7x	36.14x	13.71x	46.62x
PB Ratio	3.62x	4.95x	4.33x	2.33x	4.94x	7.67x	10.58x	5.96x	1.7x	5.49x

Source: NSE (30-May-2025)

1

01-June-2025

## NEWSLETTER (FY25 EARNINGS UPDATES)

NIFTY 50: Financial Year 2026 has started with a lot of global turmoil transpiring flow of events thereby setting stage for a global reset.

Event	Remarks	Date	NIFTY 50 Close	Change (d-o	– d)
Global Trade Tensions	US-China Tariff Escalation:	30-May-25	24,751		-83
& Tariffs	<ul> <li>Multiple rounds of tariff increases (up to 245%) and</li> </ul>	29-May-25	24,834		81
	retaliatory measures by China, including rare earth export	28-May-25	24,752		-74
	quotas, have increased global uncertainty.	27-May-25	24,826		-175
	• Periodic pauses and rollbacks provided temporary relief, but	26-May-25	25,001		148
	the overall environment remains volatile.	23-May-25	24,853		243
	Impact on India:	22-May-25	24,610		-204
	• While India was not directly targeted, global supply chain	21-May-25	24,813		130
	disruptions and shifts in trade policy have indirect effects on	20-May-25	24,684		-262
	Indian exporters and importers.	19-May-25	24,945		-74
	<ul> <li>India-UK FTA signed, offering potential export growth</li> </ul>	16-May-25	25,020		-42
	opportunities	15-May-25	25,062		395
Geopolitical Risks	India-Pakistan Tensions:	14-May-25	24,667		89
	• April-May 2025 saw a brief military escalation, including	13-May-25	24,578		-346
	airstrikes and missile exchanges, followed by a ceasefire.	12-May-25	24,925	1	917
	• Market volatility spiked during the conflict but normalized	9-May-25	24,008		-266
	post-ceasefire.	8-May-25	24,274	<b></b>	-141
	Middle East & Russia-Ukraine:		24,414		35
	Ongoing conflicts and ceasefire negotiations in Israel-Gaza     and Russia Ukraina add to global rick promiums and	6-May-25	24,380		-82
	and Russia-Ukraine add to global risk premiums and commodity price volatility.	5-May-25	24,461		114
	·· · ·	2-May-25	24,347		13
Monetary Policy &	RBI Policy Actions:	30-Apr-25	24,347		-2
Liquidity	• 25bps repo rate cut in April 2025; stance shifted to	· ·			-2
	'Accommodative'.	29-Apr-25	24,336		289
	<ul> <li>RBI revised FY26 GDP growth forecast down to 6.5% (from 6.7%), CPI inflation revised down to 4%.</li> </ul>	28-Apr-25	24,329		
	<ul> <li>Aggressive liquidity infusion (~INR 3 lakh crore) via open</li> </ul>	25-Apr-25	24,039		-207
	market operations to support banking system.	24-Apr-25	24,247		-82
	Global Central Banks:	23-Apr-25	24,329		162
	• US Fed and PBOC policy shifts, including rate cuts and	22-Apr-25	24,167		42
	liquidity measures, continue to influence FII flows and	21-Apr-25	24,126		274
	currency volatility.	17-Apr-25	23,852	· · · · · · · · · · · · · · · · · · ·	414
Global Macro Data &	US Economic Data:	16-Apr-25	23,437		109
Credit Ratings	<ul> <li>Signs of recession (rising unemployment, bond yield spikes),</li> </ul>	15-Apr-25	23,329		500
oreannage	Moody's US credit rating downgrade.	11-Apr-25	22,829		429
	• US policy responses (tariff pauses, fiscal stimulus) closely	9-Apr-25	22,399		-137
	watched by global investors.	8-Apr-25	22,536		374
	China's Economic Measures:	7-Apr-25	22,162		-743
	• LPR cuts to support growth, currency appreciation	4-Apr-25	22,904		-346
	impacting global trade dynamics.	3-Apr-25	23,250		-82
	India Credit Rating Upgrade	2-Apr-25	23,332		167
	• Gets upgraded to 'BBB' with a 'Stable' trend in rating by	1-Apr-25	23,166		-354
Market Sentiment &	Morningstar DBRS, a global sovereign credit rating agency Volatility Indicators:	India VI	X continues to re	emain elevat	ted
Flows	• India VIX spiked during geopolitical events, normalized as				
	risks subsided.	India VIX Index 016.0775 H17.7275 L	• 1D • NSE ● ≈ 16.0775 C17.0300 +0.9525 (+5.)	92%)	
	FII Activity:	17.0250 0.0000 1	7.0250		
	• FII flows turn positive on back of block deals, post conflict	Vol !	BUY		
	resolutions & expected positive trade developments				
Outlook for FY26 (from	Risks:				
events so far)	• Persistent global trade tensions, geopolitical flashpoints,				
	and external shocks.	li de la de	▋▎▏ ▝▝▋₽₽₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩		
	Opportunities:	ting the second	│ <sup>○</sup> धरन │ │ <mark>पहरणप्रस्थान्ध∔</mark> हे <mark>ह</mark> े <sup>8</sup> 44ह	***	
	• India's proactive policy response, FTA with UK, and strong				
	domestic liquidity position the market for selective	<b>17</b> TradingVi	iew		T
	domestic inquidity position the market for selective				
	outperformance.	2025 Fe	eb Mar A	pr May	Jun
	outperformance. Key Watch points:	2025 Fe	eb Mar A	pr May	Jun
	outperformance.	2025 Fe	eb Mar A	pr May	Jun

# NEWSLETTER (FY25 EARNINGS UPDATES)



Thyrocare Technologies Ltd. & Suraksha Diagnostics: Stock Price appreciation by c.54% & c.26% respectively since our recommendation and CMP as on 30-May-2025

Investment Thesis:

Thyrocare operating primarily as B2B player marked by lowest cost of testing charges amongst peers yet ranked high in testing quality (critical parameter in healthcare), highest ratio of NABL Accredited labs to Total Labs, highest no. of tests performed amongst peers, improving financial growth metrics

Suraksha Diagnostics operating primarily as B2C player with regional dominance in the Eastern markets being able to command high premiums in testing charges (likely to sustain further despite competition as discussed with management), proceeds from IPO providing liquidity, growth visibility from strategic expansion plans

FY25 Financial Performance (Actuals):

- Thyrocare Technologies: Revenue, EBITDA & PAT growth of 20%, 39% and 31% respectively (Y-o-Y) in FY25 vs FY24
- Suraksha Diagnostics: Revenue, EBITDA & PAT growth of 15%, 19% and 34% respectively (Y-o-Y) in FY25 vs FY24

Thyrocare (INR Cr.)	FY22(A)	FY23(A)	FY24(A)	FY25	(A)
Revenue	589	527	572		687
% Y-o-Y	19%	(11%)	9%	Ź	20%
Gross Margin %	71.2%	69.0%	70.9%	72	.2%
EBITDA %	39.9%	22.8%	24.0%	27	.7%
PAT %	28.5%	12.0%	11.9%	13.	.0%
Debt (Short+Long)	21	23	42		25
Equity	527	535	528	Ĺ	547
Debt/Equity	0.04x	0.04x	0.08x	0.0	)5x
NWC	101	89	51		43
NWC (days)	63	62	32		23
CF0	113	129	168		191
CFI	(24)	(39)	(91)	(	53)
CFF	(89)	(86)	(85)	(1	30)
CFO + CFI + CFF	0	4	(8)		8
Cash + Bank Bal.	14	28	40		54
CFO / EBITDA %	48%	108%	122%	10	01%
			6		
Company Name		Thyroca		aksha	
CMP (INR)		1,05	50	324	
Current Market Cap (IN	R Cr.)	5,56	50	1,672	
PE		61.3	3x	54.0x	

Check	Remarks
✓	Diagnostics sector market size to grow at 10-12% CAGR from FY24 to FY28 (higher than previous growth rates)
~	Normalization of Covid revenues in FY23 leading to drop Y-o-Y (common across players). Post that growth witnessed
~	Our interaction with doctors / sector specialists indicated positive uptick in healthcare testing going forward
✓	<ul> <li>Better / comparative growth record compared to Peers</li> <li>Reasonable valuation</li> </ul>
~	Not Rated on back of low reliance on debt due to healthy CFO / EBITDA
<b>√</b>	Key metrics of D/E, WC cycle etc. within our internal benchmarks
	✓

Note: Indicative List for knowledge purposes (Actual Parameters considered are more to reflect potential risks & upsides)

Suraksha (INR Cr.)	FY22(A)	FY23(A)	FY24(A)	FY25(A)
Revenue	223	190	219	252
% Y-o-Y	59%	(15%)	15%	15%
Gross Margin %	72.9%	85.6%	87.5%	88.3%
EBITDA %	28.1%	23.1%	32.0%	33.1%
PAT %	9.2%	3.1%	10.4%	12.2%
Debt (Short+Long)	100	97	90	89
Equity	146	156	179	210
Debt/Equity	0.68x	0.62x	0.50x	0.42x
NWC	(1)	(3)	1	8
NWC (days)	-ve	-ve	2	12
CFO	58	44	60	63
CFI	(43)	(21)	(35)	(40)
CFF	(14)	(24)	(25)	(24)
CF0 + CFI + CFF	0	(1)	0	(0)
Cash + Bank Bal.	45	55	55	20
CFO / EBITDA %	92%	100%	86%	76%

Click here to access full equity research note (Public Version)

01-June-2025

# **NEWSLETTER** (FY25 EARNINGS UPDATES)



- Standard Glass Lining Ltd.: Stock Price appreciated by c.40% since our recommendation & CMP as on 30-May-2025
  - Investment Thesis: Track record of higher revenue growth rate than peers along with improvement in margins, recent IPO and upgrade in credit ratings from CRISIL, expected Industry tailwinds, benefits from strategic partnerships expected to drive future growth
  - Investment Consideration:

Growth in revenue along with improvement in operating margins

Augmented by change in product mix, increase in exports, extensive experience of promoters in driving the business

New products introduction complemented by strategic partnerships:

- Customized and innovative product offerings complemented by strategic collaborations with HHV Pumps, Asahi Glassplant, GL Hakko, Gale Process Solutions to tap global sales
- Launching (a) shell & tube heat exchangers in licensing agreement with AGI Inc., Japan with applications in clean rooms with Indian market size of INR 2,000 Cr. (b) semiconductor industry related low leaching, high corrosion resistant glass

 72 types of products manufactured with 18 to be launched Repeat customers contributing significant portion of operating revenues

FY24 & H1FY25 contribution from repeat customers ~53.5% & 56.5% respectively. Long standing relationships in excess of 3 years with 13 of top 20 customers.

Parameter	Check	Remarks			
Industry Tailwinds	~	Slowdown in end user industries coming to an end with expected growth from here on			
Historical Performance	~	Revenue growth along with margins expansion			
Revenue Visibility	~	New product launches, strategic collaboration with bigger players			
Peer Comps & Relative Valuation	~	<ul> <li>Better growth record compared to Peers</li> <li>Reasonable valuation</li> </ul>			
Credit Rating	<b>√</b>	Upgraded by CRISIL			
Financial Ratios	✓	Key metrics of D/E, WC cycle etc. within our internal benchmarks			
Note: Indicative List for knowledge purposes (Actual Parameters considered are more to reflect potential risks & upsides)					

- FY25 Financial Performance (Actuals):
  - Revenue, EBITDA & PAT growth of 13%, 13% and 14% respectively (Y-o-Y) in FY25 vs FY24

Particulars (INR Cr.)	FY22(A)	FY23(A)	FY24(A)	FY25(A)
Revenue	240	498	544	614
% Y-o-Y	89%	107%	9%	13%
Gross Margin %	52.0%	42.6%	41.6%	43.9%
EBITDA %	16.8%	17.2%	17.4%	17.5%
PAT %	10.4%	10.7%	10.9%	11.0%
Debt (Short+Long)	70	82	129	68
Equity	69	156	409	713
Debt/Equity	1.01x	0.53x	0.32x	0.10x
NWC	146	160	291	385
NWC (days)	221	117	195	229
CFO	(7)	2	(65)	5
CFI	(30)	(29)	(157)	(160)
CFF	37	33	232	141
CF0 + CFI + CFF	0	5	10	(14)
Cash + Bank Bal.	0	5	52	122
CFO / EBITDA %	(18%)	2%	(69%)	5%

## **KEY DEVELOPMENTS\***

## New Product Launch confirmation

- Glass lined shell & tube heat exchangers launched (14-May-2025) developed in collaboration with AGI Group Japan
- Exclusive 20 year license to assemble the heat exchangers in India
- India market size of the product at INR 2,000 Cr. with potential to cater to exports (exc.

Japan)

Commencement of Operations at Unit-5 of S2 Engineering Industry Pvt. Ltd. (WOS)

DCCO from 15-Mat-2025. This is expected to scale operations and enhance overall efficiency

CMP (INR)	184
Current Market Cap (INR Cr.)	3,671
PE	57x

Click here to access full equity research note (Public Version)

\*Post our coverage

# NEWSLETTER (FY25 EARNINGS UPDATES)



- Danish Power: Stock Price appreciated by c.28% since our recommendation & CMP as on 30-May-2025
  - Investment Thesis: Prospective mainboard Company available on SME exchange with strong prospects of revenue growth on back of 70% capacity expansion backed by upgrade in credit ratings from CRISIL (in April'25) driven by strong management and track record
  - Investment Consideration:

Unexecuted order book of INR 400 Cr. (as on Feb'25) to be executed in next 8 to 9 months providing revenue visibility for FY26:

 Order book position has improved from INR 371 Cr. (as on Sep'24) on back of order inflows

Growth in revenue along with improvement in operating margins

- FY25 revenues expected to be INR 420 to 430 Cr. (est. ~INR 278 Cr. till Dec'24) with operating margins to sustain at 19-20% in medium term driven by higher contribution from inverter duty segment, economies of scale on back of capacity expansion
  - Reported EBITDA % of 19.8% till Dec'24

Capacity expansion from 4,681 MVA to 8,000 MVA from IPO proceeds

Our analysis indicates at 85% of capacity utilization, Company has potential to generate north of INR 580 Cr. of revenues from transformer segment

Parameter	Check	Remarks
Industry Tailwinds	~	Transformer capacity fully booked with rising power demand
Historical Performance	<b>~</b>	Revenue growth along with margins expansion
Revenue Visibility	~	Unexecuted order book for 8-9 months + Upcoming capacity for further upside
Peer Comps & Relative Valuation	~	<ul> <li>Better / comparative growth record compared to Peers</li> <li>Reasonable valuation</li> </ul>
Credit Rating	✓	Upgraded by CRISIL
Financial Ratios	✓	Key metrics of D/E, WC cycle etc. within our internal benchmarks
		owledge purposes (Actual Parameters ect potential risks & upsides)

- FY25 Financial Performance (Actuals):
  - Revenue, EBITDA & PAT growth of 28%, 48% and 51% respectively (Y-o-Y) in FY25 vs FY24

Particulars (INR Cr.)	FY22(A)	FY23(A)	FY24(A)	FY25(A)
Revenue	149	189	332	427
% Y-o-Y		27%	76%	28%
Gross Margin %	17.4%	20.0%	25.9%	29.3%
EBITDA %	7.1%	8.6%	16.8%	19.4%
PAT %	3.5%	4.5%	11.4%	13.3%
Debt (Short+Long)	28	14	13	4
Equity	35	44	82	320
Debt/Equity	0.80x	0.31x	0.16x	0.01x
NWC	43	30	61	145
NWC (days)	105	58	67	124
CF0	6	29	26	(19)
CFI	(6)	(10)	(7)	(41)
CFF	2	(18)	(4)	165
CFO + CFI + CFF	1	1	14	105
Cash + Bank Bal.	5	6	20	125
CFO / EBITDA %	53%	179%	46%	(23%)



#### **RELATIVE STOCK PERFORMANCE**

Sat 01 Feb 25 Mar Apr May Jun

Value creation via share price appreciation on back of strong reported earnings, margins expansion leading to EPS accretion

CMP (INR)	1,026/-
Current Market Cap (INR Cr.)	2,021
PE	34.6x

Click here to access full equity research note (Public Version)

# NEWSLETTER

(FY25 EARNINGS UPDATES)



**Thangamayil, Sky Gold, PN Gadgil**: Stock Price appreciated by c.16%, c.8%, c.6% respectively since our recommendation

Investment Thesis: Market cap expansion driven by strong year on year revenue growth and sustainability (with potential improvement) of existing margins. Sky Gold operates as pure manufacturing play while Thangamayil, PN Gadgil & Senco Gold are growing as retail players with strong presence in South, West & East parts of India respectively

FY25 Financial Performance (Actuals):

- FY25 Revenue, EBITDA & PAT growth (Y-o-Y) •
- Thangamayil: 28%, 3% and (4%) respectively
- Sky Gold: 103%, 154% and 228% respectively
- PN Gadgil: 26%, 24% and 41% respectively

Thanga (INR Cr.)	FY22(A)	FY23(A)	FY24(A)	FY25(A)
Revenue	2,193	3,153	3,827	4,911
% Y-o-Y	21%	44%	21%	28%
Gross Margin %	9.0%	9.4%	9.6%	8.8%
EBITDA %	3.9%	4.9%	5.5%	4.5%
PAT %	1.8%	2.5%	3.2%	2.4%
Debt (Short+Long)	420	571	532	797
Equity	324	389	493	1,102
Debt/Equity	1.29x	1.47x	1.08x	0.72x
NWC	745	966	1,176	1,954
NWC (days)	124	112	112	145
CFO	(79)	10	330	(424)
CFI	(21)	(86)	(30)	(138)
CFF	94	78	(293)	637
CFO + CFI + CFF	(7)	2	8	75
Cash + Bank Bal.	17	76	82	242
CFO / EBITDA %	(92%)	7%	156%	(194%)

Sky Gold (INR Cr.)	FY22(A)	FY23(A)	FY24(A)	FY25(A)	PAT %	2.7%	
Revenue	786	1,154	1,745	3,548	Debt (Short+Long)	336	
% Y-o-Y	(1%)	47%	51%	103%	Equity	282	
Gross Margin %	3.6%	4.3%	6.0%	7.1%	Debt/Equity	1.19x	
EBITDA %	2.6%	3.1%	4.4%	5.5%	NWC	563	
PAT %	2.1%	1.6%	2.3%	3.7%	NWC (days)	80	
Debt (Short+Long)	92	146	310	630	CFO	73	
Equity	77	98	244	684	CFI	(22)	
Debt/Equity	1.20x	1.49x	1.27x	0.92x	CFF	(46)	
NWC	116	151	364	823	CFO + CFI + CFF	5	
NWC (days)	54	48	76	85	Cash + Bank Bal.	45	
CFO	(7)	(6)	(137)	(273)	CFO / EBITDA %	65%	
CFI	(2)	(20)	(107)	(157)	Company Nama		
CFF	10	43	239	427	Company Name CMP (INR)		
CFO + CFI + CFF	1	17	(5)	(3)	Current Market Cap (INR Cr.)		
Cash + Bank Bal.	1	18	77	175	PE		_
CFO / EBITDA %	(36%)	(18%)	(178%)	(139%)	Click here to access	full and	

Parameter	Check	Remarks						
Industry Tailwinds	✓	Indian Domestic jewelry sector t grow at 16% CAGR (FY24 to FY28)						
Historical Performance	✓	Revenue growth along with margins expansion						
Revenue Visibility	✓	Recurring / stable demand arising from festivals, weddings, daily wear along with shift from unorganized to organized players						
Peer Comps & Relative Valuation	✓	<ul> <li>Better / comparative growth record compared to Peers</li> <li>Reasonable valuation</li> </ul>						
Credit Rating	✓	Upgraded for Thangamayil & PN Gadgil while stable for Sky Gold						
Financial Ratios	✓	Key metrics of D/E, WC cycle etc. within our internal benchmarks						

Note: Indicative List for knowledge purposes (Actual Parameters considered are more to reflect potential risks & upsides)

CFI	(21)	(86)	(30)	(138)	PN	PN Gadgil (INR Cr.) FY22(A		FY23(A)	FY24(A)	FY25(A)
CFF	94	78	(293)	637		Revenue				
CFO + CFI + CFF	(7)	2	8	75		Y-0-Y	2,556	76%		
Cash + Bank Bal.	17	76	82	242		oss Margin %	9.8%			9.1%
CFO / EBITDA %	(92%)	7%	156%	(194%)		ITDA %	4.4%			4.4%
Sky Gold (INR Cr.)	FY22(A)	FY23(A)	FY24(A)	FY25(A)	PA	Т %	2.7%	2.1%	2.5%	2.8%
Revenue	786	1,154	1,745	3,548	De	bt (Short+Long)	336	324	455	930
% Y-o-Y	(1%)	47%	51%	103%	Eq	uity	282	366	534	1,554
Gross Margin %	3.6%	4.3%	6.0%	7.1%	De	bt/Equity	1.19x	0.89x	0.85x	0.60x
EBITDA %	2.6%	3.1%	4.4%	5.5%	NV	VC	563	505	848	1,815
PAT %	2.1%	1.6%	2.3%	3.7%	NV	VC (days)	80	41	51	86
Debt (Short+Long)	92	146	310	630	CF	0	73	105	6	(675)
Equity	77	98	244	684	CF	1	(22)	(45)	(49)	(424)
Debt/Equity	1.20x	1.49x	1.27x	0.92x	CF	F	(46)	(55)	51	1,167
NWC	116	151	364	823	CF	0 + CFI + CFF	5	5	9	68
NWC (days)	54	48	76	85	Ca	sh + Bank Bal.	45	49	80	529
CFO	(7)	(6)	(137)	(273)	CF	0 / EBITDA %	65%	85%	2%	(201%)
CFI	(2)	(20)	(107)	(157)				Thomas	Clay Cold	
CFF	10	43	239	427		Company Name		Thanga	Sky Gold	PN Gadgil
CFO + CFI + CFF	1	17	(5)	(3)		CMP (INR)		1,904	393	549
Cash + Bank Bal.	1	18	77	175		Current Market Cap (INR Cr.)		5,992	5,774	7,444 34.1x
CFO / EBITDA %	(36%)	(18%)	(178%)	(139%)	PE       50.5x       43.5x         Click here to access full equity research note (Public Version)					

# NEWSLETTER (FY25 EARNINGS UPDATES)



PCBL Chemical Ltd.: Stock Price appreciated by c.10% since our recommendation & CMP as on 30-May-2025

- Investment Thesis: Market leader in domestic carbon black segment with capacity expansion along with product diversification, new products development in progress backed by RPSG Group.
- Investment Consideration:

Leadership in domestic carbon black segment with capacity ramp-up plan & increase in sales of specialty grade which is margin accretive

Company has total installed capacity of 678,000 MTPA of Rubber Black and 92,000 MTPA of Specialty Black which is set to cross total 1,000,000 MTPA by FY27 (increase of ~30%) spread across 5 locations in India

Acquisition of Aquapharm chemicals – India's largest and globally top 3 phosphonate producer with diversified product applications

Production capacity of 130,000 MTPA with manufacturing plants in India, USA and Saudi Arabia and further addition of 38,000 MTPA in FY25

Nanovace Technologies Ltd. (JV between PCBL & Kindia holding 51% & 49% stake respectively) to commence manufacturing in FY27 / FY28 with topline potential of INR 2,000 Cr. & EBITDA margins of 50%

Ordered machines for setting up pilot plant for obtaining product approval from customers

Parameter	Check	Remarks					
Industry Tailwinds	✓	Demand from carbon black segment & chemicals segment					
Historical Performance	✓	Revenue growth along with margins expansion					
Revenue Visibility	✓	Diversified across carbon black, chemicals & power generation					
Peer Comps & Relative Valuation	✓	<ul> <li>Better / comparative growth record compared to Peers</li> <li>Reasonable valuation</li> </ul>					
Credit Rating	✓	AA rated with Stable outlook					
Financial Ratios	✓	Key metrics of D/E, WC cycle etc. within our internal benchmarks					
Note: Indicative List for knowledge purposes (Actual Parameters considered are more to reflect potential risks & upsides)							

- FY25 Financial Performance (Actuals):
  - Revenue, EBITDA & PAT growth of 31%, 29% and (11%) respectively (Y-o-Y) in FY25 vs FY24

Particulars (INR Cr.)	FY22(A)	FY23(A)	FY24(A)	FY25(A)
Revenue	4,446	5,774	6,420	8,404
% Y-o-Y	67%	30%	11%	31%
Gross Margin %	29.5%	24.6%	30.4%	30.9%
EBITDA %	14.7%	12.7%	16.2%	15.9%
PAT %	9.5%	7.6%	7.6%	5.2%
Debt (Short+Long)	786	1,029	4,983	5,571
Equity	2,622	2,839	3,250	3,709
Debt/Equity	0.30x	0.36x	1.53x	1.50x
NWC	798	726	908	1,467
NWC (days)	65	46	52	64
CFO	290	504	1,105	760
CFI	(541)	(552)	(4,214)	(690)
CFF	217	(31)	3,381	(64)
CFO + CFI + CFF	(34)	(78)	272	6
Cash + Bank Bal.	159	96	385	389
CFO / EBITDA %	44%	69%	107%	57%

## **RELATIVE STOCK PERFORMANCE**



Dec	2025	Feb	Mar	Apr	May	Jun
				,		

Our analysis indicates that long term growth story for the Company remains intact

• Q4FY25 carbon black realization dropped as foreign players sold huge quantities in Asian countries at very low prices

CMP (INR)	398
Current Market Cap (INR Cr.)	15,046
PE	34.6x

Click here to access full equity research note (Public Version)

# **NEWSLETTER** (FY25 EARNINGS UPDATES)



- Dhabriya Pollywood Ltd.: Stock Price is down by c.9% since our recommendation & CMP as on 30-May-2025
  - Investment Thesis: Increasing real estate demand from urbanization along with promoter's extensive experience in the market driving the Company to innovate and produce multiple SKUs along with repeat orders from large RE players such as DLF, M3M, Mahindra Group etc.
  - Investment Consideration:

Durable, sustainable and versatile products to meet increasing real estate demand from urbanization

Easy to install products with quicker turnaround time ensures real estate developers compliance with RERA timelines

Premium looking products at lower cost compared to wood / marble provides a suitable alternative

Established market position with diversified customer base & products

- Promoter has been in business for over 25 years with strong understanding of market dynamics and healthy relationships with customers and suppliers
- Order book of ~INR 135 Cr.+ (Sep'24) for uPVC and modular furniture with regular deliveries to marquee clients such as M3M, DLF etc. provides product offtake and revenue receipts visibility
- PAN India presence with ~800+ dealers/distributors further strengthens position in extruded PVC profile

Existing capacity has potential to achieve ~1.75x (FY24) revenues without any major capex

Parameter	Check	Remarks					
Industry Tailwinds	~	Product demand will capture th growth from rapid urbanizatio in the real estate sector					
Historical Performance	✓	Revenue growth along with margins expansion					
Revenue Visibility	✓	Regular updates on BSE with order wins from DLF, M3M etc.					
Peer Comps & Relative Valuation	~	<ul> <li>Better / comparative growth record compared to Peers</li> <li>Reasonable valuation</li> </ul>					
Credit Rating	<b>√</b>	CRISIL BBB/Stable					
Financial Ratios	✓	Key metrics of D/E, WC cycle etc. within our internal benchmarks					
Note: Indicative L		wledge purposes (Actual Parameters					

considered are more to reflect potential risks & upsides)

- FY25 Financial Performance (Actuals):
  - Revenue, EBITDA & PAT growth of 11%, 21% and 28% respectively (Y-o-Y) in FY25 vs FY24

Particulars (INR Cr.)	FY22(A)	FY23(A)	FY24(A)	FY25(A)
Revenue	134	171	212	235
% Y-o-Y	26%	28%	24%	11%
Gross Margin %	36.7%	37.3%	44.8%	47.5%
EBITDA %	10.3%	10.8%	14.7%	16.0%
PAT %	3.8%	4.9%	6.6%	7.6%
Debt (Short+Long)	54	57	53	53
Equity	60	69	82	100
Debt/Equity	0.89x	0.83x	0.64x	0.53x
NWC	59	63	61	74
NWC (days)	162	133	106	115
CFO	10	14	32	17
CFI	(7)	(13)	(20)	(12)
CFF	(1)	(1)	(10)	(5)
CF0 + CFI + CFF	2	1	2	1
Cash + Bank Bal.	4	5	7	7
CFO / EBITDA %	72%	76%	102%	46%

#### **CONSOLIDATING & BUILDING ON GAINS**

Quarterly Results									PRODUCT SEGMENTS				
Consolidated F	Consolidated Figures in Rs. Crores / View Standalone												
	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales +	40.08	36.79	43.75	40.16	50.48	50.19	54.65	52.02	54.78	58.69	58.05	54.90	63.47
Expenses +	34.60	34.07	39.41	35.31	43.97	43.29	47.06	44.22	46.08	49.45	48.87	46.05	53.23
Operating Profi	5.48	2.72	4.34	4.85	6.51	6.90	7.59	7.80	8.70	9.24	9.18	8.85	10.24
OPM %	3.67%	7.39%	9.92%	12.08%	12.90%	13.75%	13.89%	14.99%	15.88%	15.74%	15.81%	16.12%	16.13%
Other Income +	0.11	0.07	0.06	0.02	0.15	0.05	0.12	0.14	0.22	0.12	0.18	0.12	0.16
Interest	0.86	0.91	1.01	0.98	1.11	1.30	1.24	1.21	1.33	1.18	1.26	1.18	1.24
Depreciation	0.89	0.85	0.88	0.90	1.15	1.47	1.66	1.86	1.91	1.93	2.18	2.42	2.10
Profit before tax	3.84	1.03	2.51	2.99	4.40	4.18	4.81	4.87	5.68	6.25	5.92	5.37	7.06
Tax %	4.06%	37.86%	14.74%	24.75%	21.36%	25.84%	25.57%	31.62%	28.35%	25.60%	29.39%	28.86%	23.94%
Net Profit +	3.30	0.65	2.14	2.25	3.45	3.10	3.59	3.33	4.06	4.65	4.18	3.82	5.37
EPS in Rs	3.05	0.60	1.98	2.08	3.19	2.86	3.32	3.08	3.75	4.30	3.86	3.53	4.96

Consistent improvement in margins along with expansion in topline

CMP (INR)	359
Current Market Cap (INR Cr.)	392
PE	21.7x

Click here to access full equity research note (Public Version)

## STANDARD DISCLOSURES:

- Research Analyst has served as an officer, director or employee of subject company(ies): No
- We or our associates have received compensation from the subject company(ies) in the past 12 months: No
- We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: No
- We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months -No
- We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report -No
- We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies)- No
- Nature of financial interest in subject company, if any -Nil
- We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of Research Report No
- Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report-No.
- We or our Associates or Research Analyst are engaged in market making of subject company No
- By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
- There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.

## **REGULATORY DISCLOSURES:**

Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta (SEBI registration no. INH000018896).

Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.

The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness. The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.

For any queries or grievances: Mr. Nishant Gupta | Email: <u>nishant.gupta@mcapital.in</u> | Contact Number: 8171433387 | Website: <u>www.mcapital.in</u> | Twitter: <u>@Mcapital\_In</u>

#### **RATING RATIONALE:**

Minerva Capital Research Solutions endeavors to provide objective opinions and recommendations. Ratings are assigned to stocks according to their fair value vs current market price and then categorizes them as Buy, Hold, Reduce, Sell. The performance horizon is one year unless specified and fair value is defined as analyst's valuation for a stock.

- Buy:> 15%
- Hold: -5% to 15%
- Reduce: -15% to -5%
- Sell: <-15%